Biomedicine & Pharmacotherapy · 2019 · 45 citations · 38 references
MedicineCardiologyPharmacologyChemotherapyInflammationMolecular PharmacologyAnthracycline CardiotoxicityAnti-inflammatory PharmacologyCardiac PharmacotherapyCardiovascular PharmacologyHeart FailureHeart Failure PharmacotherapyCardiac Fibrosis ModulationCardiovascular Drug PharmacologyCollagen Degradation InhibitionDrug-induced ApoptosisHeart Failure PharmacologyInflammatory Cytokine EffectsMechanisms Of Cardiac InjuryOxidative Stress Injury
Heart failure is a major cause of morbidity and mortality worldwide. LongShengZhi capsule (LSZ), a traditional Chinese medicine, is used for treatment of patients with vascular diseases. Herein we investigated the effect of LSZ treatment on doxorubicin (DOX)-induced heart failure in mice. C57BL/6 mice randomly in 3 groups received following treatment: Control group, mice were fed normal chow; DOX group, mice were intraperitoneally injected DOX to induce heart failure and fed normal chow; and LSZ group, mice were injected DOX and fed normal chow containing LSZ. DOX induced heart failure as evidenced by increased serum creatine kinase, lactic dehydrogenase and α-hydroxybutyrate dehydrogenase, and cardiac fibrosis. However, LSZ treatment substantially inhibited DOX-induced heart failure parameters. Mechanistically, LSZ reduced collagen content and fibrosis by inhibiting expression of collagen type I α1 (COL1α1), COL1α2, α-smooth muscle actin and transforming growth factor β1. In addition, DOX-induced cell apoptosis was inhibited by LSZ, coupled with reduced caspase 3 activity and mRNA expression. LSZ decreased inflammatory cytokine levels. More importantly, LSZ decreased oxidative stress by inducing expression of anti-oxidative stress enzymes including superoxide dismutase 1 (SOD1), SOD2, catalase and glutathione peroxidase 1 through activation of forkhead box O3A and sirtuin 3. In conclusion, our study demonstrates that LSZ reduces heart failure by reducing production of reactive oxygen species and inhibiting inflammation/apoptosis. Our study also suggests the potential application of LSZ for heart failure treatment.
38
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
John J.V. McMurray, Milton Packer, Akshay S. Desai et al. · New England Journal of Medicine · 2014 · 6.8K citations · Full text
Medicine, Cardiology, Pharmacology +11
Caroline F. Thorn, Connie Oshiro, Sharon Marsh et al. · Pharmacogenetics and Genomics · 2010 · 1.6K citations · Full text
Calorie Restriction Reduces Oxidative Stress by SIRT3-Mediated SOD2 Activation
Xiaolei Qiu, Katharine Brown, Matthew D. Hirschey et al. · Cell Metabolism · 2010 · 1.3K citations · Full text